Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Jeannie Joughin has also held various scientific positions including Senior Research Scientist, Post-Doctorate and Senior Post-Doctorate positions in Australia at The Alfred Hospital, The Walter & Eliza Hall Institute, as well as internationally in Austria (University Clinic, Innsbruck) and Switzerland (Ludwig Institute for Cancer Research, Lausanne). Dr. Joughin began her career in the pharmaceutical industry in 1992 as a Clinical Research Manager with Bristol-Myers Squibb. After managing local trials in oncology and cardiology, she moved into New Product Commercialisation as the interface between the medical and marketing departments. From there, Dr. Joughin worked in Brand Management. After successfully completing several marketing roles in the National Stroke Foundation, MediMark International and Mayne Pharma, Dr. Joughin joined CSL Biotherapies in 2005 as Director, Pharmaceuticals Marketing and In-licensing. She assumed responsibility for a portfolio of pharmaceutical products from several licensing partners in various therapeutic areas. Her responsibilities included extending distribution agreements with current partners when appropriate and securing various new product distribution agreements. As Vice President, Business Development at CSL Behring Dr Joughin was responsible for managing business licensing arrangements and relationships. This involved close liaison with CSL Behring’s Commercial Development Team in the US, Germany and Switzerland. Now as Vice President, Corporate Development and member of the executive team, Jeannie Joughin is responsible for business development, strategic alliances, alliance management, marketing and clinical activities. Dr Joughin will be working cross-functionally to select and prioritize Enable’s global portfolio.